Chemotherapy: what is its role in meningioma?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ern.12.108PMID 23082735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

  2012cited by this paper
• Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

  2012cited by this paper
• Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

  2011cited by this paper
• Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

  2011cited by this paper
• Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease

  2011cited by this paper
• Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

  2011cited by this paper
• A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma.

  2011cited by this paper
• Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab.

  2011cited by this paper
• Angiogenesis Inhibitors: Current Strategies and Future Prospects

  2010cited by this paper
• Aberrant signaling pathways in meningiomas

  2010cited by this paper
• Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor

  2010cited by this paper
• Medical therapies for meningiomas

  2010influential reference
• Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

  2009cited by this paper
• Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

  2009cited by this paper
• Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas

  2008cited by this paper
• Methylation status of MGMT gene promoter in meningiomas.

  2008cited by this paper
• Is there an association between meningioma and hormone replacement therapy?

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Recurrent meningioma

  2007cited by this paper
• Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.

  2007cited by this paper
• Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

  2007cited by this paper
• Exogenous hormone use and meningioma risk

  2007cited by this paper
• Role of radiation therapy in treating intracranial meningiomas.

  2007cited by this paper
• Salvage chemotherapy With CPT-11 for recurrent meningioma

  2006cited by this paper
• Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study

  2006cited by this paper
• Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma

  2006cited by this paper
• A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study

  2005cited by this paper
• Prolonged Oral Hydroxyurea and Concurrent 3d-Conformal Radiation in Patients with Progressive or Recurrent Meningioma: Results of a Pilot Study

  2005cited by this paper
• Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.

  2004cited by this paper
• Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity

  2004cited by this paper
• Temozolomide for treatment-resistant recurrent meningioma

  2004cited by this paper
• Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea

  2004cited by this paper
• Meningioma Pathology, Genetics, and Biology

  2004cited by this paper
• Meningioma: Current treatment options and future directions

  2004cited by this paper
• Intracranial meningiomas: diagnosis and treatment

  2004cited by this paper
• Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.

  2002cited by this paper
• Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.

  2002cited by this paper
• Treatment of high risk or recurrent meningiomas with hydroxyurea.

  2002cited by this paper
• Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells.

  2001cited by this paper
• Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.

  2001cited by this paper
• Hydroxyurea Chemotherapy for Unresectable or Residual Meningioma

  2000cited by this paper
• Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.

  2000cited by this paper
• Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.

  1997cited by this paper
• Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.

  1997cited by this paper
• Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.

  1997cited by this paper
• Expression and activation of epidermal growth factor receptors in meningiomas.

  1997cited by this paper
• Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

  1997cited by this paper
• Chemotherapy for meningiomas

  1996cited by this paper
• Adjuvant combined modality therapy for malignant meningiomas.

  1996cited by this paper
• Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.

  1991cited by this paper
• Epidermal growth factor receptor expression in 72 meningiomas

  1990cited by this paper

• RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation

  2024cites this paper
• Necrotizing Parasagittal Meningioma in Patient with Systemic Lupus Erythematosus after Treatments with Methotrexate and Hydroxychloroquine

  2023cites this paper
• Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis

  2022cites this paper
• A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

  2022cites this paper
• Is an Immunosuppressive Microenvironment a Characteristic of Both Intra- and Extraparenchymal Central Nervous Tumors?

  2021cites this paper
• Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo

  2021cites this paper
• Consensus core clinical data elements for meningiomas.

  2021cites this paper
• An Overview of Managements in Meningiomas

  2020cites this paper
• Pharmacotherapeutic options for atypical meningiomas

  2019cites this paper
• Meningiomas’ Management: An Update of the Literature

  2016cites this paper
• Intracranial Meningiomas: A 30-Year Experience and Literature Review.

  2016cites this paper
• Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature

  2016cites this paper
• Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series

  2016cites this paper
• Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade

  2016cites this paper
• EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases

  2016cites this paper
• Chapter 30 – Spinal Cord Tumors

  2016cites this paper
• Non-malignant brain tumors

  2015cites this paper
• Innovative Therapeutic Strategies in the Treatment of Meningioma.

  2015cites this paper
• Decrease in serine protease HtrA1 expression correlates with grade and recurrence in meningiomas.

  2015cites this paper
• New Developments in Management of Meningioma

  2015cites this paper
• The importance of microsurgery in childhood meningioma: a case report

  2014cites this paper
• Assessment of improved organ at risk sparing for meningioma: light ion beam therapy as boost versus sole treatment option.

  2014cites this paper
• Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex

  2014cites this paper
• Recent developments in chemotherapy for meningiomas: a review.

  2013cites this paper
• Metastatic Meningioma Presenting as Cancer of Unknown Primary

  2013cites this paper